AstraZeneca cholesterol drug Crestor drove the company’s third-quarter financials forward as generic competition significantly affected other medications.
Although revenues fell 2% to approximately $8.2bn, Crestor reported a sales increase of 14% to $1.66bn, with US sales rising 20% and total prescriptions up 3%.
Go deeper with GlobalData
The company also benefitted from strong performances from the antipsychotic Seroquel and Seroquel XR, with sales rising 4% and 24% respectively.
AstraZeneca’s oncology portfolio fell significantly, however, with a number of patent expiries impacting on drug performance. Arimidex sales fell 44% to $176m, whereas Casodex declined by 9%.
AstraZeneca chief executive David Brennan said: "We have delivered a third-quarter revenue and core earnings performance in line with our expectations, against the backdrop of anticipated generic competition and government price interventions."
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
